AMEX:CPP (USA)

Cancer Prevention Pharmaceuticals Inc

$ 0 0 (0%)
Volume: 0 Avg Vol (1m): 0
Market Cap $: - Enterprise Value $: -
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value 0
Net Current Asset Value 0
Tangible Book 0
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength :

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history

Profitability & Growth :

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history

» CPP's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with AMEX:CPP

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 0    SIC : 0
Compare OTCPK:NUVPF OTCPK:ADMD OTCPK:RSPI OTCPK:YBAO OTCPK:ULUR OTCPK:NRXCF OTCPK:ACUR OTCPK:LBLTF OTCPK:PUFXF OTCPK:BKIT OTCPK:RLMD AMEX:IGC NAS:MYOS OTCPK:CBICF OTCPK:SBFM OTCPK:PVCT OTCPK:AQSZF OTCPK:PTLF OTCPK:AOLS NAS:APRI
Traded in other countries
Address
Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.

Ratios

Current vs industry vs history

Dividend & Buy Back

Current vs industry vs history

Valuation & Return

Current vs industry vs history

More Statistics

Analyst Estimate

Piotroski F-Score Details